Press release content from BusinessWire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

Global Oral Mucositis Epidemiology Insights to 2025 - ResearchAndMarkets.com

September 11, 2018

DUBLIN--(BUSINESS WIRE)--Sep 11, 2018--The “Oral Mucositis - Epidemiology Insights to 2025” report has been added to ResearchAndMarkets.com’s offering.

Oral Mucositis - Epidemiology Forecast To 2025 provides an overview of the disease and global historical and forecasted epidemiological data of Oral Mucositis for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan till 2025.

Oral Mucositis is considered as one of the most common oral problems associated with cancer therapy. It is reported that Oral mucositis occurs in up to 20% to 40% of adult cancer patients receiving conventional chemotherapy for solid tumors, about 80% of patients receiving high-dose chemotherapy before haematopoietic stem cell transplantation, and almost all patients receiving radiotherapy for head and neck cancer. The Oral mucositis also occurs in the 70% of the patients with cancers of the mouth, oropharynx, hypopharynx, larynx, nasopharynx, and salivary glands. It has been reported that approximately 500,000 cases of oral mucositis occurs in U.S. The incidence of oral mucositis varies across populations of patients with cancer and is related to individual patient factors and the type of therapy being received.


The report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment optionsThe report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2015-2025The report includes the overall incidence, grade specific, gender specific and indication specific incidence of Oral Mucositis in the 7MM - United States, EU5 (France, Germany, Italy, Spain and UK) and Japan

For more information about this report visit https://www.researchandmarkets.com/research/76vqfz/global_oral?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180911005383/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/11/2018 06:55 AM/DISC: 09/11/2018 06:55 AM


All contents © copyright 2019 The Associated Press.All rights reserved.